TNFRSF11B and renal cell carcinoma: A study by Beuselinck [25] involving 129 RCC patients treated with anti-VEGFR-TKIs revealed that an elevated RANK/OPG ratio was associated with shorter time to bone metastasis, shorter median overall survival from initial diagnosis and shorter median progression-free survival.